Genentech Says Data Positive From Tecentriq Lung Cancer Study
September 27 2019 - 11:20AM
Dow Jones News
By Michael Dabaie
Roche Holding AG's (RO.EB, ROG.EB) Genentech said data was
positive from the Phase III IMpower110 study evaluating Tecentriq
in advanced non-squamous and squamous non-small cell lung
cancer.
Genentech said the study looked at Tecentriq as a monotherapy in
advanced non-squamous and squamous non-small cell lung cancer
without ALK or EGFR mutations.
The study showed Tecentriq monotherapy helped people with
advanced non-small cell lung cancer with high PD-L1 expression live
longer compared with chemotherapy alone, Genentech said.
The company said it will share the data with health authorities
globally, including the U.S. Food and Drug Administration and
European Medicines Agency.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 27, 2019 11:05 ET (15:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024